Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKLB-V02
- Development stage
- Phase 1
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
SKLB-V02 is a recombinant protein developed by the State Key Laboratory of Biotherapy at Sichuan University and West China Hospital for the treatment of fibrotic diseases, particularly systemic sclerosis (SSc) and its associated complications. It functions as a TGF-beta trap, incorporating the extracellular domain of the human TGF-beta receptor II (TβRII). By acting as a decoy receptor, SKLB-V02 binds with high affinity to and neutralizes the pro-fibrotic cytokines TGF-β1 and TGF-β3. This inhibition prevents the activation of the TGF-beta signaling pathway, which is a primary driver of myofibroblast differentiation and excessive extracellular matrix production in scleroderma and pulmonary fibrosis. The drug is currently undergoing Phase I clinical evaluation in China to assess its safety, tolerability, and preliminary efficacy in patients with diffuse systemic sclerosis and interstitial lung disease.
- Other names
- SKLB-V02 recombinant proteinSKLB-V-02 recombinant proteinSKLB-V 02 recombinant protein
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB3 (Transforming growth factor beta 3)
Beyond the preview
Go deeper on SKLB-V02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKLB-V02.